Skip to main content
Premium Trial:

Request an Annual Quote

Shamrock Signs Proteomics Pact with Intra-Cellular Therapies

NEW YORK, Aug. 5 (GenomeWeb News) - Shamrock Structures of Woodbridge, Ill., today announced that it has signed an agreement to provide integrated structural proteomics services to Intra-Cellular Therapies.


Under the pact, Shamrock will perform structure-activity relationship co-crystallization, synchrotron data collection, and structure determination of an Intra-Cellular Therapies protein target to which inhibitors are bound. The agreement includes an upfront fee and milestone payments. Additional terms of the deal were not disclosed.


New York-based Intra-Cellular Therapies is a privately held biopharmaceutical firm developing drugs for central nervous system disorders, such as depression, schizophrenia, Alzheimer's and Parkinson's disease.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.